Am J Transplant, Volume 19, Suppl 3 Archives - Page 171 of 214 - ATC Abstracts

2019 American Transplant Congress
Impact of MELD-Na Course (Delta MELD-Na) on Outcome after Liver Transplantation
G. Silberhumer¹, G. Gyoeri¹, L. Unger², G. Harpain¹
¹Transplant Surgery, Medical University Vienna, Vienna, Austria, ²Institute for Mathematics and Bioscience, Medical University Vienna, Vienna, Austria
*Purpose: Currently, MELD Score listing is state of the art for liver transplant recipients. Our department could show by our own institutional data and confirmed…
2019 American Transplant Congress
Patients With Persistently Low MELD-Na Scores Continue To Be At Risk Of Liver Related Death
N. Mazumder, K. Atiemo, S. Montag, A. Daud, A. Kho, M. Abecassis, J. Levitsky, D. Ladner
Northwestern Memorial Hospital, Chicago, IL
*Purpose: The Model for End Stage Liver Disease-Sodium (MELD-Na) score is a reliable predictor of 90-day mortality however its long term predictive ability is unclear,…
2019 American Transplant Congress
Case Series: Anti-Thymocyte Globulin as a Treatment for Steroid-Refractory Severe Acute Hepatitis in Children
A. L. Peters, A. Miethke, K. Campbell
Department of Pediatrics, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: Pediatric severe acute hepatitis (SAH), when not attributed to acetaminophen toxicity, is commonly hypothesized to be caused by a non-typeable viral infection and/or immune…
2019 American Transplant Congress
Obesity Induced IL-18 Production Impairs FOXP3+ Treg Function and Increases Risk of Primary Graft Dysfunction in Lung Transplant Recipients
W. W. Hancock¹, T. Zhang¹, U. H. Beier¹, A. Samanta¹, R. Han¹, L. Wang¹, J. Jiao¹, J. M. Diamond², D. S. Wilkes³, D. J. Lederer⁴, R. A. Simmons², J. D. Christie², T. Akimova²
¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Virginia, Charlottesville, VA, ⁴Columbia University, New York, NY
*Purpose: Lung transplantation is a life-saving treatment for terminal lung diseases but long-term outcomes are poor, beginning with possible development of primary graft disease (PGD)…
2019 American Transplant Congress
The Molecular Features of Chronic Lung Allograft Dysfunction (CLAD) in Transbronchial and Endobronchial Mucosa Biopsies
M. D. Parkes¹, K. M. Halloran¹, J. Chang², P. F. Halloran and the INTERLUNG study group¹
¹University of Alberta, Edmonton, AB, Canada, ²ATAGC, University of Alberta, Edmonton, AB, Canada
*Purpose: Chronic lung allograft dysfunction (CLAD), the major long-term problem in lung transplantation, requires new strategies for prevention and management. However, CLAD is infrequently diagnosed…
2019 American Transplant Congress
Robotic Kidney Transplantation For Obese Patients: First Year Experience In Single Institute
S. Lee¹, L. A. Cantrell², A. Agarwal¹, S. K. Rasmussen¹, S. Pelletier¹, K. Brayman¹, J. Oberholzer¹
¹Division of Transplant Surgery, Department of Surgery, University of Virginia Health Sciences Center, Charlottesville, VA, ²Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia Health Sciences Center, Charlottesville, VA
*Purpose: Obesity with end-stage renal disease significantly impacts intraoperative and postoperative complications in kidney transplantation. Robot-assist procedures have been an attractive modality to overcome barriers…
2019 American Transplant Congress
Endovascular Repair Of Abdominal Aortic Aneurysms In Kidney Transplant Recipients
S. Kwon¹, D. Jung¹, Y. Kim¹, S. Park², S. Yoon²
¹Department of Vascular and Transplant Surgery, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of, ²Department of Vascular and Transplant Surgery, The Catholic Universtiy of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of
*Purpose: The possibility to diagnosis abdominal aortic aneurysm (AAA) in patients who underwent kidney transplantation (KT) is increasing. Immunosuppressive agents may effect on AAA progression.…
2019 American Transplant Congress
Mortality around the One-Year Survival Metric after Liver Transplantation in the United States
C. Blebea¹, P. Chatterjee², A. Nathan¹, J. Diamond¹, H. J. Goldberg², A. Courtwright¹
¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²Brigham and Women’s Hospital, Boston, MA
*Purpose: Liver transplant programs in the United States are evaluated on one-year survival, among other factors. This may create an unintended incentive to continue life-sustaining…
2019 American Transplant Congress
Early Readmission After Renal Transplant As A Valuable Quality Measure
S. Kim¹, A. Osband¹, B. Merhi², G. Bayliss², R. Gohh², P. Morrissey¹
¹Surgery, Rhode Island Hospital, Providence, RI, ²Nephrology, Rhode Island Hospital, Providence, RI
*Purpose: Patient and graft survival have been criticized as imprecise measures of transplant program quality. Thirty-day (30d) readmission rates, available nationally and attainable locally, may…
2019 American Transplant Congress
Daratumumab for Treatment of Antibody-Mediated Rejection in a Kidney Transplant Recipient
S. C. Jordan¹, R. Vescio², M. Toyoda³, N. Ammerman¹, E. Huang¹, A. Peng¹, S. Sethi¹, R. Najjar¹, K. Lim¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Antibody-Mediated Rejection (ABMR) is a severe form of rejection mediated by B-cells, plasma cells and antibodies. The consequences to the patients with ABMR are…